US EditionPublished • loading... • Updated
StockWatch: CytomX Shares Yo-Yo on Colorectal Cancer Data
CytomX Therapeutics (NASDAQ: CTMX) drew attention a few days ago after its six-year-old, up-to-$1.68 billion cancer collaboration with Astellas Pharma (Tokyo: 4503) was terminated by the Japanese pharma giant, but the setback hardly registered with investors of the South San Francisco, CA, biotech. Instead, what drew investors to CytomX stock on March 16 was its announcement of positive dose expansion data from a Phase I trial (NCT06265688) asse…
1 Articles
1 Articles
StockWatch: CytomX Shares Yo-Yo on Colorectal Cancer Data
CytomX Therapeutics (NASDAQ: CTMX) drew attention a few days ago after its six-year-old, up-to-$1.68 billion cancer collaboration with Astellas Pharma (Tokyo: 4503) was terminated by the Japanese pharma giant, but the setback hardly registered with investors of the South San Francisco, CA, biotech. Instead, what drew investors to CytomX stock on March 16 was its announcement of positive dose expansion data from a Phase I trial (NCT06265688) asse…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
